Diamond Publications - Search Results

Search Again...

These results only include publications that have been reviewed and processed by Diamond Light Source. To also view papers that have not yet been processed click here.

You can use the folder icon under Actions to collate papers as required. You can then click on View Folder in the left-hand navigation to review and/or download your folder.

One item found (0 items not approved).

Instruments / Technical Area	Publication Details	Published	Actions
I03-Macromolecular Crystallography	First-in-class inhibitors of the ribosomal oxygenase MINA53 Radoslaw Nowak , Anthony Tumber , Eline Hendrix , Mohammad Salik Zeya Ansari , Manuela Sabatino , Lorenzo Antonini , Regina Andrijes , Eidarus Salah , Nicola Mautone , Francesca Romana Pellegrini , Klemensas Simelis , Akane Kawamura , Catrine Johansson , Daniela Passeri , Roberto Pellicciari , Alessia Ciogli , Donatella Del Bufalo , Rino Ragno , Mathew L. Coleman , Daniela Trisciuoglio , Antonello Mai , Udo Oppermann , Christopher J. Schofield , Dante Rotili Journal Of Medicinal Chemistry 1091 DOI: 10.1021/acs.jmedchem.1c00605 Diamond Proposal Number(s): [10619] Open Access Show Abstract ▼ Abstract: MINA53 is a JmjC domain 2-oxoglutarate-dependent oxygenase that catalyzes ribosomal hydroxylation and is a target of the oncogenic transcription factor c-MYC. Despite its anticancer target potential, no small-molecule MINA53 inhibitors are reported. Using ribosomal substrate fragments, we developed mass spectrometry assays for MINA53 and the related oxygenase NO66. These assays enabled the identification of 2-(aryl)alkylthio-3,4-dihydro-4-oxoypyrimidine-5-carboxylic acids as potent MINA53 inhibitors, with selectivity over NO66 and other JmjC oxygenases. Crystallographic studies with the JmjC demethylase KDM5B revealed active site binding but without direct metal chelation; however, molecular modeling investigations indicated that the inhibitors bind to MINA53 by directly interacting with the iron cofactor. The MINA53 inhibitors manifest evidence for target engagement and selectivity for MINA53 over KDM4–6. The MINA53 inhibitors show antiproliferative activity with solid cancer lines and sensitize cancer cells to conventional chemotherapy, suggesting that further work investigating their potential in combination therapies is warranted.	Nov 2021

Instruments / Technical Area

Publication Details

Published

Actions

I03-Macromolecular Crystallography

First-in-class inhibitors of the ribosomal oxygenase MINA53